PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
 
Br J Cancer. 1993 September; 68(3): 594–598.
PMCID: PMC1968411

High-dose chemotherapy and autologous bone marrow transplantation for patients with poor prognosis nonseminomatous germ cell tumours.

Abstract

Twenty-one patients with poor prognosis nonseminomatous germ cell tumours (six with extreme burden disease at presentation in whom partial remission had been achieved with initial induction therapy, and 15 with recurrent disease after induction therapy) were treated with high-dose chemotherapy and autologous bone marrow transplantation (BMT). The first six received etoposide 3.0 g m-2, ifosfamide 6.0 g m-2 and carboplatin 1.2 g m-2 (Regimen 1), and the subsequent 15 received etoposide 2.4 g m2 (continuous infusion), cyclophosphamide 7.2 g m-2 and carboplatin 0.8 g m-2 (Regimen 2) followed by infusion of previously stored autologous marrow. Regimen 1 was associated with considerable renal toxicity and mucositis, whereas Regimen 2 was relatively well tolerated. Two patients died as a consequence of the treatment: one of candidemia and one of interstitial pulmonary fibrosis. Only one of 17 patients who were autografted in or approaching marker remission subsequently developed disease progression (event-free survival 82%, 95% confidence interval [CI] 55% to 94%), whereas all four patients who had progressive disease at autografting subsequently developed further disease progression and died. Fourteen patients remain well and free of disease 0.5 to 6.5 years (median 3.3) post-BMT (event-free survival 67%, 95% CI 43% to 83%). A strategy of prompt reinduction followed by high-dose chemotherapy and autologous BMT at the first sign of failure of standard therapy may allow cure to be a realistic expectation.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (960K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, Thomas ED. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988 Oct;6(10):1562–1568. [PubMed]
  • Birch R, Williams S, Cone A, Einhorn L, Roark P, Turner S, Greco FA. Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol. 1986 Mar;4(3):400–407. [PubMed]
  • Blijham G, Spitzer G, Litam J, Zander AR, Verma DS, Vellekoop L, Samuels ML, McCredie KB, Dicke KA. The treatment of advanced testicular carcinoma with high dose chemotherapy and autologous marrow support. Eur J Cancer. 1981 Apr;17(4):433–441. [PubMed]
  • Broun ER, Nichols CR, Tricot G, Loehrer PJ, Williams SD, Einhorn LH. High dose carboplatin/VP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumors. Bone Marrow Transplant. 1991 Jan;7(1):53–56. [PubMed]
  • Broun ER, Nichols CR, Einhorn LH, Tricot GJ. Salvage therapy with high-dose chemotherapy and autologous bone marrow support in the treatment of primary nonseminomatous mediastinal germ cell tumors. Cancer. 1991 Oct 1;68(7):1513–1515. [PubMed]
  • Broun ER, Nichols CR, Kneebone P, Williams SD, Loehrer PJ, Einhorn LH, Tricot GJ. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med. 1992 Jul 15;117(2):124–128. [PubMed]
  • Buckner CD, Clift RA, Fefer A, Funk DD, Glucksberg H, Neiman PE, Paulsen A, Storb R, Thomas ED. High-dose cyclophosphamide (NSC-26271) for the treatment of metastatic testicular neoplasms. Cancer Chemother Rep. 1974 Sep-Oct;58(5 Pt 1):709–714. [PubMed]
  • Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov;7(11):1748–1756. [PubMed]
  • Cheson BD, Lacerna L, Leyland-Jones B, Sarosy G, Wittes RE. Autologous bone marrow transplantation. Current status and future directions. Ann Intern Med. 1989 Jan 1;110(1):51–65. [PubMed]
  • Droz JP, Pico JL, Ghosn M, Gouyette A, Baume D, Piot G, Ostronoff M, Theodore C, Beaujean F, Hayat M. Long-term survivors after salvage high dose chemotherapy with bone marrow rescue in refractory germ cell cancer. Eur J Cancer. 1991;27(7):831–835. [PubMed]
  • Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol. 1990 Nov;8(11):1777–1781. [PubMed]
  • Elias AD, Eder JP, Shea T, Begg CB, Frei E, 3rd, Antman KH. High-dose ifosfamide with mesna uroprotection: a phase I study. J Clin Oncol. 1990 Jan;8(1):170–178. [PubMed]
  • Feuer EJ, Kessler LG, Baker SG, Triolo HE, Green DT. The impact of breakthrough clinical trials on survival in population based tumor registries. J Clin Epidemiol. 1991;44(2):141–153. [PubMed]
  • Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res. 1984 Apr;44(4):1693–1697. [PubMed]
  • Harstrick A, Schmoll HJ, Wilke H, Köhne-Wömpner CH, Stahl M, Schöber C, Casper J, Bruderek L, Schmoll E, Bokemeyer C, et al. Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J Clin Oncol. 1991 Sep;9(9):1549–1555. [PubMed]
  • Herzig GP. Autologous marrow transplantation in cancer therapy. Prog Hematol. 1981;12:1–23. [PubMed]
  • Loehrer PJ, Sr, Einhorn LH, Williams SD. VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. J Clin Oncol. 1986 Apr;4(4):528–536. [PubMed]
  • Loehrer PJ, Sr, Lauer R, Roth BJ, Williams SD, Kalasinski LA, Einhorn LH. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med. 1988 Oct 1;109(7):540–546. [PubMed]
  • Motzer RJ, Gulati SC, Crown JP, Weisen S, Doherty M, Herr H, Fair W, Sheinfeld J, Sogani P, Russo P, et al. High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated. Cancer. 1992 Jan 15;69(2):550–556. [PubMed]
  • Mulder PO, de Vries EG, Koops HS, Splinter T, Maas A, van der Geest S, Mulder NH, Sleijfer DT. Chemotherapy with maximally tolerable doses of VP 16-213 and cyclophosphamide followed by autologous bone marrow transplantation for the treatment of relapsed or refractory germ cell tumors. Eur J Cancer Clin Oncol. 1988 Apr;24(4):675–679. [PubMed]
  • Nichols CR, Tricot G, Williams SD, van Besien K, Loehrer PJ, Roth BJ, Akard L, Hoffman R, Goulet R, Wolff SN, et al. Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol. 1989 Jul;7(7):932–939. [PubMed]
  • Nichols CR, Andersen J, Lazarus HM, Fisher H, Greer J, Stadtmauer EA, Loehrer PJ, Trump DL. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol. J Clin Oncol. 1992 Apr;10(4):558–563. [PubMed]
  • Reece DE, Barnett MJ, Connors JM, Fairey RN, Fay JW, Greer JP, Herzig GP, Herzig RH, Klingemann HG, LeMaistre CF, et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol. 1991 Oct;9(10):1871–1879. [PubMed]
  • Rosti G, Albertazzi L, Salvioni R, Pizzocaro G, Cetto GL, Bassetto MA, Marangolo M. High-dose chemotherapy supported with autologous bone marrow transplantation (ABMT) in germ cell tumors: a phase two study. Ann Oncol. 1992 Dec;3(10):809–812. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK